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Abstract: Neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy followed by mesorectal excision is the
current standard treatment in locally advanced rectal cancer (LARC) and the lack of complete response represents
a major problem that compromises long-term patient survival. However, there is a lack of robust established
markers predictive of response to this preoperative treatment available in the clinical routine. The tumor
suppressor microRNA (miR)-199b directly targets the PP2A inhibitor SET, which has been involved in 5-FU
resistance, and its downregulation has been found to correlate with poor outcome in metastatic colorectal cancer.
Here, we studied the functional effects of miR-199b on 5-FU sensitivity after its ectopic modulation, and its
expression was quantified by real-time-PCR in a cohort of 110 LARC patients to evaluate its potential clinical
significance. Interestingly, our findings demonstrate that miR-199b enhances the sensitivity of colorectal
cancer cells to 5-FU in a SET-dependent manner, and that both miR-199b overexpression and SET inhibition
are able to overcome resistance to this drug using an acquired 5-FU-resistant model. MiR-199b was found
downregulated in 26.4% of cases and was associated with positive lymph node levels after chemoradiotherapy
(CRT, p = 0.007) and high pathological stage (p = 0.029). Moreover, miR-199b downregulation determined
shorter overall (p = 0.003) and event-free survival (p = 0.005), and was an independent predictor of poor
response to preoperative CRT (p = 0.004). In conclusion, our findings highlight the clinical impact of miR-199b
downregulation predicting poor outcome and pathological response in LARC, and suggest the miR-199b/SET
signaling axis as a novel molecular target to prevent the development of resistance to 5-FU treatment.
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1. Introduction
Colorectal cancer (CRC) is a gastrointestinal cancer with the highest incidence rate and is the fourth
leading cause of cancer-related death worldwide [1], with rectal cancer accounting for approximately
30% of all colorectal tumors [2]. The guidelines of the National Comprehensive Cancer Network
recommend a multidisciplinary approach consisting of 5-fluorouracil (5-FU)-based preoperative CRT
followed by total mesorectal excision (TME) surgery that represents the treatment of choice for locally
advanced rectal cancer (LARC) [3,4]. Although 5-FU is more used, the oral 5-FU prodrug capecitabine
has recently been defined as a useful alternative option [5]. This therapeutic regimen has improved
the management of LARC patients and was established after several studies demonstrating that
CRT before TME led to lower local recurrence rates than TME followed by adjuvant CRT or TME
alone [6,7]. In addition, there is an increasing interest in a novel “watch and wait” approach where
highly selected patients with a complete response after neoadjuvant CRT can escape surgery in order
to improve their quality of life [8]. The pathological response after the introduction of preoperative
CRT is of high clinical relevance since those patients who achieve a complete pathological response
are expected to experience significantly improved long-term survival rates compared to others with
residual tumor [9,10]. Unfortunately, distant metastases are developed in more than one-third of
patients within 10 years from diagnosis and complete pathological response only occurs in less than
20% of cases [11]. The lack of effective biomarkers established in clinical practice able to predict
pathological tumor response before treatment represents a major current limitation in LARC clinical
management. Some postsurgical prognostic factors have been proposed [12,13], but only limited
data about potential markers of response to preoperative CRT have been reported to date [14–16].
Therefore, the identification of patients who have a higher possibility of responding to preoperative CRT
would be of high relevance in order to improve patient outcomes, reduce both treatment morbidity and
delays in the resection of the primary tumor, and allow potential nonresponders to receive alternative
therapeutic strategies.
MicroRNAs (miRs) are small noncoding single-stranded RNAs that post-transcriptionally inhibit
specific target genes. MiRs have been largely reported to play key roles in human cancer, and they
can act as oncogenes or tumor suppressors depending on their targets [17]. Due to the ability to
be easily detected in both tumor tissue and blood, miRs have been proposed as promising markers
with clinical impact in rectal cancer [18,19]. Despite the well-known role of miR-199b as a tumor
suppressor in human cancer, only a limited number of studies have explored the role of miR-199b
in CRC. This miR has been reported to contribute to CRC progression through the regulation of the
SIRT1/CREB/KISS1 signaling pathway [20], and circNSD2 was found to target miR-199b in CRC cells
thereby leading to DDR1/JAG1 activation and facilitating the development of metastatic disease [21].
SET is an endogenous inhibitor of the tumor suppressor PP2A [22]. SET has been reported to play
oncogenic roles and be overexpressed in a large number of tumor types. In fact, its inhibition has
been proposed as a novel anticancer strategy [23]. Our group reported that miR-199b directly targets
SET leading to the activation of the tumor suppressor PP2A, and affects cell viability and oxaliplatin
sensitivity in CRC cells. In addition, miR-199b downregulation was found as a frequent alteration
predictive of poor outcome in metastatic CRC [24], and a very recent study has shown that high levels
of both tissue and exosomal miR-199a/b could be associated with better response to CRT in LARC [25].
However, its potential clinical and therapeutic significance in this disease remains to be fully clarified.
In this study, we investigate the role of miR-199b determining resistance to 5-fluorouracil treatment
and analyze its potential clinical impact in the subgroup of LARC patients. We observed that miR-199b
enhances 5-FU antitumor properties in a SET-dependent manner, and that acquired resistance to 5-FU
is overcome by ectopic expression of miR-199b, SET silencing or treatment with the SET inhibitor
compound FTY720. To evaluate its clinical relevance, we quantified miR-199b in a cohort of 110 LARC
patients, observing that miR-199b downregulation is a common alteration that independently predicts
poor outcome and pathological response to neoadjuvant chemoradiotherapy.
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2. Experimental Section
2.1. Cell Cultures and Transfection
The human colorectal cancer cell lines SW480 (ATCC CCL-228) and HT-29 (ATCC HTB-38), were
purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Authentication
was performed by the authors in all cases (LGC Standards). Cell lines were maintained in RPMI-1640
(Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) and were grown at 37 ◦C in a 5% CO2
atmosphere. Media were supplemented with penicillin G (100 U/mL), and streptomycin (0.1 mg/mL).
Cells were treated with 5-FU (Calbiochem, San Diego, CA, USA) and FTY720 (Calbiochem) at the
indicated concentrations for each experimental condition. For transfection experiments, CRC cells were
seeded in 6-well plates and transfected with 10 µL of Lipofectamine 2000 (Life Technologies, Carlsbad,
CA, USA) and 2 µg of SET plasmidic vector, 75 nM of SET-specific siRNAs designed and synthesized
by Dharmacon RNA Technologies or 20 nM of a miR-199b specific mirVanaTM miRNA Mimic and
Inhibitor (Ambion, Cambridge, UK). To generate 5-FU-resistant cells, SW480 cells were cultured in the
presence of increasing doses of 5-FU (three subculturing doses per concentration), starting at 0.1 µM.
In order to assess the evolution of resistance, we determined IC50 after every 5-FU concentration point,
by using an MTS assay (Promega, Madison, WI, USA) after 24 h of treatment. The resistance of every
5-FU-resistant clone was defined as the ratio between resistant and parental cells IC50 values.
2.2. Patient Samples and Pathologic Response
We retrospectively selected and included in this study a total of 110 consecutive specimens from
patients with a histological diagnosis of LARC who were treated with preoperative CRT between 2006
and 2014 at the University Hospital Fundación Jiménez Díaz, (Madrid, Spain). All cases had an accurate
preoperative locoregional staging based on a magnetic resonance image (MRI) of the pelvis and/or
transrectal ultrasound (TRUS). A full-body computed tomography scan (FBCTS) was carried out in all
patients in order to exclude metastatic disease. The patients were treated with chemoradiotherapy
regimens based on 5-FU and underwent surgery 6 to 8 weeks after neoadjuvant CRT completion.
All participants gave written informed consent for tissue storage and analysis at Fundación Jiménez
Díaz biobank, Madrid (Spain). The ethical committee institutional review board of Fundación Jiménez
Díaz University Hospital reviewed and approved the project (2018/54).
All tumor specimens derived from the surgical resection were classified according to the College of
American Pathologist guidelines for invasive carcinomas (TNM, 7th ed.). Two independent pathologists
who were blinded to patient outcome evaluated tumor regression grade according to the modified
Ryan classification that categorizes tumors into four levels of response: complete response, moderate
response, minimal response and poor response. Complete response score 0 indicates no viable cancer
cells; moderate score 1 indicates single cells or little groups of cancer cells; minimal score 2 indicates
residual cancer outgrown by fibrosis; and poor response score 3 indicates minimal or no tumor kill
with extensive residual cancer. According to clinical guidelines, every regression grade was compared
with the primary tumor [26].
2.3. Nucleic Acid Isolation
Total RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tumor biopsies, applying
RecoverAll Total Nucleic Acid Isolation kit Ambion (Thermo Fisher Scientific, Waltham, MA, USA)
following manufacturer’s instructions. Total RNA obtained was quantified using a NanoDrop
Spectrophotometer (Thermo Scientific, Waltham, MA, USA).
2.4. Quantification of miRNA Expression Levels
Total RNA was isolated using the RecoverAll Total Nucleic Acid Isolation kit (Ambion) according
to the manufacturer’s instructions. Samples were reverse transcribed using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) and mature miRNAs were
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quantified by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) using
TaqMan MicroRNA Assays (Applied Biosystems) specific for miR-199b (miR-199b-5p_000500) and
U6B as an internal control. Reactions were carried out using an Applied Biosystems 7500 Sequence
Detection System. Conditions: 95 ◦C for 10 min, followed by 45 cycles of 95 ◦C for 15 s, and 60 ◦C for
1 min. Analysis of relative gene expression data was performed using the 2−∆∆CT method [27], where
∆∆CT = (CT, Target Gene-CT, U6B) Tumor-(CT, Target Gene-CT, U6B) Normal Control. As previously
described [24], downregulation of miR-199b was considered when the expression in a sample was lower
than the mean minus standard deviation (SD) of the patient cohort, corresponding to 0.266 fold change.
2.5. Cell Viability Assay
Cell proliferation was measured in triplicate wells by the MTS assay in 96-well plates using
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), according to the
manufacturer’s instructions.
2.6. Analysis of Caspase Activation
Quantification of caspase-3/7 activities was performed using the caspase Glo-3/7 assay kit
(Promega Corp, Madison, WI, USA). Briefly, 5× 103 cells were seeded in a black-walled 96-well plate, and
the Z-DEVD reagent, the luminogenic caspase-3/7 substrate containing a tetrapeptide Asp–Glu–Val–Asp,
was added with a 1:1 ratio of reagent to sample. After 90 min at room temperature, the substrate
cleavage by activated caspase-3 and -7, and the intensity of a luminescent signal was measured by
a FLUOstar OPTIMA luminometer (BMG Labtech, Cary, NC, USA). Differences in caspase-3/7 activity
are expressed as fold change in luminescence.
2.7. Western Blot Analysis
Protein extracts were isolated using TRIzol Reagent (Invitrogen) following the manufacturer’s
indications, clarified (12,000× g, 15 min, 4 ◦C), denatured and subjected to SDS-PAGE and Western blot.
Antibodies used were rabbit polyclonal anti-SET (Abcam, Cambridge, UK) and mouse monoclonal
anti-βactin (Sigma, St. Louis, MO, USA). Proteins were detected with the appropriate secondary
antibodies conjugated to alkaline phosphatase (Sigma) by chemiluminescence using Tropix CSPD and
Tropix Nitro Block II (Applied Biosystems).
2.8. Statistical Analysis
Statistical analyses were performed using SPSS 20 for windows (SPSS Inc, Chicago, IL USA).
We applied the χ2 test (Fisher exact test) based on the bimodal distribution of data to analyze the
correlation between miR-199b downregulation and the clinical and pathological variables.
Overall survival (OS) was defined as the time from the date of diagnosis to the date of death or
last follow-up. Event-free survival (EFS) was defined as the time from diagnosis until any primary,
local or distant recurrence, death or last follow-up. Kaplan–Meier plots and survival comparisons were
performed by means of a log-rank test if the proportional hazard assumption was fulfilled and Breslow
otherwise. The Cox proportional hazards model was adjusted taking into consideration significant
parameters in the univariate analysis. The cutoff point for miR-199b expression was determined as
previously described [24]. This work was carried out in accordance with Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK) guidelines [28]. Data represented for transfection
experiments are mean of three independent experiments ± s.d. Statistical comparisons were carried
out by two-sided t-test analyses; p < 0.05 was considered statistically significant.
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3. Results
3.1. MiR-199b Sensitizes to 5-FU Treatment in a SET-Dependent Manner
To fully clarify the biological relevance of miR-199b regulating 5-FU efficacy, we first confirmed
previous findings reporting that miR-199b overexpression enhances 5-FU antitumor effects. As expected,
we observed that miR-199b overexpression significantly enhanced 5-FU-induced antitumor properties
in both SW480 and HT-29 cells in comparison with those cells transfected with a negative control
miRNA (Figure 1A). As the effects of miR-199b downregulation have not been previously reported
we transfected both cell lines with a specific anti-miR-199b to further validate the observations
overexpressing miR-199b. Interestingly, we observed a reduction in sensitivity to 5-FU in both cases
(Figure 1B). These results confirm that miR-199b is involved in modulating the sensitivity of CRC to
5-FU treatment.
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Figure 1. MiR-199b enhances sensibility to 5-fluorouracil (5-FU) treatment. MTS assay showing cell
growth in SW480 and HT-29 cells treated with 5-FU (1 µM) and transf c ed with (A) pre-miR-199b or
(B) anti-miR-199b; * p < 0.05; ** p < 0.01.
As SET is a miR-199b target which has been previously described to play a key role
in miR-199b-mediated oxaliplatin resensitization in metastatic CRC, we next analyzed the potential role
of SET in the effects observed on 5-FU treatment after modulation of miR-199b expression. Interestingly,
we observed that the ectopic expression of SET completely restored the enhanced 5-FU antitumor
effects induced by miR-199b overexpression in SW480 cells in both cell growth and caspase-dependent
apoptosis. However, when we silenced SET in SW480 cells ectopically expressing miR-199b, we
observed that the cell gro th reduction after 5-FU treatm nt was even greater. In concordance, both
miR-199b expression and SET silenc ng markedly enhanced cell apoptosis (Figure 2A). Similar results
were found in HT-29 cells (Figure 2B). Altogether, these results would indicate t at SET regulation is
a key event that mediates miR-199b-induced effects on 5-FU sensitivity.
3.2. The miR-199b/SET Axis Emerges as a Novel Target to Overcome 5-FU Resistance
To further explore the potential relevance of miR-199b in determining a 5-FU resistance phenotype,
we treated SW480 and SW480R cells with different 5-FU concentrations (0.5 and 1 µM) for 72 h and
observed that the ectopic expression of miR-199b resensitized SW480R cells to 5-FU at levels similar to
SW480 cells (Figure 3).
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observing an almost three-fold decrease in miR-199b expression in these cells in compariso
with parental SW480 (5-FU-sensitive, Figure 4A). In concordance with these results, SW480R cells
showed a marked increase in SET expression levels (Figure 4B). In order to investigate whether SET
plays a role in determining miR-199b-dependent sensitivity to 5-FU treatment and its potential value as
a novel target to overcome 5-FU resistance, we performed an MTS assay in SW480R cells treated with
5-FU. In concordance with our last observations, we found that miR-199b overexpression markedly
resensitized SW480R cells to 5-FU. Moreover, we observed that both genomic and pharmacological
SET inhibition had similar effects (Figure 4C). To further confirm these observations, caspase activation
assays were carried out, observing that miR-199b overexpression and SET inhibition strongly enhanced
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5-FU-induced cell apoptosis in SW40R cells (Figure 4D). Two different siRNAs were used for SET
silencing and similar effects were observed (Figure S1A). No differences were found between controls
including pre-miR-C-, siRNA-C- and DMSO (Figure S1B). Altogether, these results appear to indicate
that the miR-199b/SET signaling axis is involved in 5-FU resistance and emerges as a novel druggable
target to overcome that resistance using compounds such as FTY720.
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3.3. Prevalence of miR-199b Downregulation and Its Association with Molecular and Clinical Parameters
To study the prevalence and clinical relevance of miR-199b, we quantified the expression of
this miR in a cohort of 110 LARC patients, observing miR-199b downregulation in 26.4% of cases
(29 out of 110). Patient characteristics are shown in Table S1. Next, we analyzed the association of low
miR-199b levels with clinical and molecular characteristics in 82 LARC patients from our cohort with
clinical follow-up data available. MiR-199b downregulation correlated with positive lymph node levels
after CRT (p = 0.007) and high pathological stage (p = 0.029). Moreover, patients with low miR-199b
levels had higher tumor size after CRT, however, statistical significance was not achieved (p = 0.143).
The association between miR-199b expression and molecular and clinical parameters are included
in Table 1.
Table 1. Association between miR-199b and clinical and molecular parameters in 82 locally advanced
rectal cancer (LARC) patients.
Parameters No. Cases No. miR-199b High (%) No. miR-199 Low (%) p
MiR-199b 82 58 (70.7) 24 (29.3)
Age 82 58 24 0.407
<70 42 28 (48.3) 14 (58.3)
≥70 40 30 (51.7) 10 (41.7)
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Table 1. Cont.
Parameters No. Cases No. miR-199b High (%) No. miR-199 Low (%) p
ECOG 1 82 58 24 0.370
0 52 35 (60.3) 17 (70.8)
1–2 30 23 (39.7) 7 (29.2)
Clinical Stage Pre-CRT 2 82 58 24 0.638
II 5 4 (6.9) 1 (4.2)
III 77 54 (93.1) 23 (95.8)
Grade Pre-CRT 73 50 23 0.185
Low 21 12 (24) 9 (39.1)
Moderate-High 52 38 (76) 14 (60.9)
ypT 3 82 58 24 0.143
0 11 10 (17.2) 1 (4.2)
1 11 10 (17.2) 1 (4.2)
2 26 16 (27.6) 10 (41.6)
3 27 19 (32.8) 8 (33.4)
4 4 2 (3.4) 2 (8.3)
x 3 1 (1.8) 2 (8.3)
ypN 4 82 58 24 0.007
N0 64 50 (86.2) 14 (58.3)
N1 14 5 (8.6) 9 (37.5)
N2 4 3 (5.2) 1 (4.2)
Pathological Stage 82 58 24 0.029
yp0 11 10 (17.2) 1 (4.2)
ypI 32 25 (43.1) 7 (29.2)
ypII 21 15 (25.9) 6 (25)
ypIII 18 8 (13.8) 10 (41.6)
1 ECOG = Eastern Cooperative Oncology Group; 2 CRT = chemoradiotherapy; 3 ypT = tumor size after CRT;
4 ypN = pathological lymph node after CRT.
Since we observed differences in both tumor size and lymph node positivity between high and
low miR-199b expression, we next analyzed which patient subgroups are different. We observed that
those cases with low tumor size (p = 0.015) and lack of lymph nodes (p = 0.006) significantly associated
with miR-199b downregulation (Table S2).
3.4. MiR-199b Predicts Pathological Response to Neoadjuvant CRT in Locally Advanced Rectal Cancer
To investigate the potential predictive value of response to preoperative CRT of miR-199b, we
grouped our patient cohort into responders and nonresponders. Interestingly, we observed that low
miR-199b expression is strongly associated with a lack of response (70.8% vs. 34.5%, p = 0.004, Table 2).
In concordance with these observations, low miR-199b expression significantly associated with a lack
of downgrading when we compared the grade pre and post-CRT in 60 cases with clinical data available
(Table S3).
Table 2. Association between miR-199b expression levels and pathological response to neoadjuvant
CRT in LARC patients.
Responders vs. Nonresponders
MiR-199b Expression No. Cases MiR-199b Low (%) MiR-199b High (%) p
Response 82 24 58 0.004
Nonresponse 1 37 17 (70.8) 20 (34.5)
Response 2 45 7 (29.2) 38 (65.5)
1 Nonresponse: poor or minimal pathological response; 2 Response: moderate or complete pathological response.
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Furthermore, we quantified SET by RT-PCR in 76 out of 82 cases with enough material available.
We found SET overexpressed in 22.4% of cases and significantly correlated with low miR-199b
expression (p = 0.004, Table S4) and lack of response to neoadjuvant CRT (p = 0.015, Table S5).
To further confirm the inverse correlation between SET and miR-199b expression, we analyzed SET by
immunohistochemistry in a set of 20 LARC cases, observing SET overexpression associated with those
patients with low miR-199b levels (Figure 5A and Table S6).
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Notably, multivariate analysis de onstrated that preoperative miR-199b expression is
an independ t predictor of respo eoadjuvant CRT in our cohort of LARC patients (p = 0.004,
Table 3).
Table 3. Univariate and multivariate logistic analyses for pathological response in 82 LARC patients.
Response 1 vs.
Nonresponse 2






Lower Upper Lower Upper
Age 0.192 0.095
<70 1.000 1.000
≥70 1.796 0.746 to 4.327 2.275 0.868 to 5.968
Gender 0.193 -
Male 1.000
Female 0.549 0.222 to 1.354 - -
Clinical Stage 0.551 -
II 1.000
III 1.307 0.543 to 3.144 - -
Grade Pre-CRT 5 0.605 -
Low 1.000
Moderate-High 1.185 0.623 to 2.252 - -
ECOG 6 0.501 -
0 1.000
1–2 1.364 0.553 to 3.363 - -
MiR-199b 0.004 0.002
High 1.000 1.000
Low 4.614 1.642 to 11.969 5.332 1.813 to 13.679
1 Response: moderate or complete pathological response; 2 Nonresponse: poor or minimal pathological response;
3 CI: confidence interval; 4 OR: odds ratio; 5 CRT: chemoradiotherapy; 6 ECOG: Eastern Cooperative Oncology Group.
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3.5. Clinical Significance of miR-199b Downregulation in Locally Advanced Rectal Cancer
To further investigate the impact of miR-199b in LARC, we next analyzed its potential value
predicting clinical outcome. For survival analyses we included those 82 LARC cases with clinical
follow-up data available, 49 were male and 33 female, with a median of age of 69 years (range: 46–85).
Interestingly, we found that the subgroup of patients with low miR-199b had a substantially shorter
OS (59 vs. 94 months, p = 0.003) and EFS (65 vs. 102 months, p = 0.005, Figure 5B).
Interestingly, multivariate analysis demonstrated that low miR-199b levels are an unfavorable
independent factor associated with both OS and EFS in our cohort (Table 4 and Table S7).
Table 4. Univariate and multivariate Cox analyses in the cohort of 82 LARC patients.
Parameters






Lower Upper Lower Upper
Age 0.261 0.184
<70 1.000 1.000
≥70 1.914 0.617 to 5.937 2.249 0.680 to 7.436
Pathological Stage 0.206 -
0–I 1.000
II–III 2.063 0.672 to 6.632 - -
ypT 4 0.204 -
0–2 1.000
3–4 1.274 0.877 to 1.850 - -
ypN 5 0.048 0.108
N− 1.000 1.000
N+ 3.336 1.011 to 11.005 2.243 0.861 to 4.544
ECOG 6 0.434 -
0 1.000
1–2 1.549 0.518 to 4.632 - -
MiR-199b 0.014 0.040
High 1.000 1.000
Low 4.036 1.328 to 12.261 3.478 1.059 to 11.425
1 OS: overall survival; 2 CI: confidence interval; 3 HR: hazard ratio; 4 ypT: tumor size after chemoradiotherapy
(CRT); 5 ypN: pathological lymph node after CRT; 6 ECOG: Eastern Cooperative Oncology Group.
4. Discussion
There is an urgent need to establish robust markers predictive of response to neoadjuvant
CRT in LARC. Although some gene signatures and specific miR profiles have shown potential
prognostic value, none of them have been well-validated and incorporated in the clinical routine [15,19].
We previously reported that miR-199b deregulation is a common alteration in metastatic CRC and
demonstrated that the PP2A inhibitor SET is a direct target of this miR [24]. PP2A is a key tumor
suppressor in human cancer due to its regulatory role in signaling pathways crucial for the tumor
cells [29,30]. Several studies have shown the high relevance of PP2A inhibition in CRC [31,32], and
the overexpression of its endogenous inhibitor SET [22] as a primary alteration to inactivate PP2A
in this disease [33]. Our group reported that SET overexpression induces cell growth and decreases the
sensitivity of CRC cells to standard chemotherapeutic agents such as oxaliplatin and 5-FU. As expected
with the reported role of SET modulating sensitivity of CRC cells to oxaliplatin and 5-FU [33], miR-199b
was found to also increase the effects of both treatments [24]. Considering that preoperative CRT
regimens in LARC are based on 5-FU, we hypothesized that this miR could have a potential clinical
and therapeutic impact on this disease. Thus, our results in Figure 1A are concordant with previous
observations indicating that miR-199b overexpression sensitizes CRC cells to 5-FU treatment [24].
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Moreover, we also used a specific anti-miR-199b, observing an expected reduction in the 5-FU antitumor
effects in both CRC cell lines tested (Figure 1B) which further confirmed the role of miR-199b modulating
sensitivity to this drug. The fact that the observed effects with the anti-miR-199b were of less intensity
is probably due to the fact that both SW480 and HT-29 cells have a low basal miR-199b expression.
Next, we showed that miR-199b sensitizes to 5-FU in a SET-dependent manner (Figure 2), similarly to the
observations previously reported with oxaliplatin [24]. In order to demonstrate the involvement of SET
we ectopically overexpressed SET in miR-199b-expressing CRC cells using a plasmidic vector without
the 3′UTR region and the specific miR-199b “seed region”, which makes miR-199b unable to inhibit the
ectopic SET. In these conditions, SET completely restored the miR-199b-induced effects demonstrating
that this miR modulates 5-FU sensitivity at least partially through its target SET. However, we cannot
claim other contributing targets in addition to SET and the total reversion could also be due to the
high ectopic overexpression levels achieved. In fact, SIRT1 is another miR-199b target which has been
shown to contribute to 5-FU resistance in CRC cells [34,35]. In addition, the enhanced effects after
FTY720 treatment could be explained by additional antitumor effects to SET inhibition such as CIP2A
downregulation [31] or by the fact that miR-199b overexpression does not lead to a total endogenous
SET inhibition [36]. In order to demonstrate the potential therapeutic value of the miR-199b/SET
axis, we generated an acquired resistant model of CRC cells to 5-FU observing that both miR-199b
overexpression and genetic or pharmacologic SET inhibition are able to overcome 5-FU resistance
(Figure 4), which suggests that these alterations could serve as novel targets for alternative therapeutic
strategies in LARC patients with a lack of response to standard preoperative CRT. In fact, the use of SET
antagonists such as FTY720 and OP449 have shown promising effects in SET-overexpressing human
tumors and could be useful in LARC patients [37,38]. Previous findings have shown that miR-199b
downregulation predicts poor outcome in metastatic CRC. Moreover, our group recently reported
that miR-199b downregulation was significantly associated with SET overexpression in a set of 29
CRC patients without metastatic disease. Notably, seven out of 29 cases had SET overexpressed, and
three out of those seven SET-overexpressing cases showed a concomitant miR-199b downregulation,
which suggests that this alteration is a contributing mechanism to deregulate SET in early-stage
CRC [39]. We observed here an inverse correlation between miR-199 and SET expression in LARC.
We found low miR-199b levels in 10 out of 17 SET-overexpressing cases, which suggest the existence of
additional mechanisms to deregulate SET in LARC. Moreover, both SET and miR-199b determined
response to neoadjuvant CRT, highlighting the clinical impact of the miR-199b/SET axis in this disease.
Although there is no current data about the potential prognostic value of miR-199b in early-stage CRC,
our results showing that low miR-199b levels predict shorter OS and EFS in LARC (Figure 5) together
with the fact that SET predicts poor outcome in CRC highlights that miR-199b could be of clinical
relevance in CRC without metastatic disease. Moreover, miR-199b downregulation predicted the lack
of response to neoadjuvant CRT in our cohort, results that are strengthened by the findings recently
reported in 65 LARC tumor samples indicating that high miR-199a/b levels predicted better response
to preoperative CRT [25]. Moreover, high exosomal miR-199b expression also correlated with CRT
response, which indicates the potential usefulness of this miR for liquid biopsies. This will need to be
validated in further randomized, controlled studies before inclusion in clinical protocols.
5. Conclusions
In conclusion, miR-199b downregulation is a frequent alteration in LARC that contributes to 5-FU
resistance in a SET-dependent manner. Moreover, both miR-199b overexpression and SET inhibition can
overcome the 5-FU-resistant phenotype. Our results indicate that low levels of miR-199b independently
predicts shorter OS and EFS, and could be used to anticipate poor pathological response to neoadjuvant
CRT in LARC patients. Altogether, our findings highlight the potential impact of the miR-199b/SET
axis as a novel therapeutic strategy in LARC, which needs to be fully confirmed in forthcoming studies
including ex vivo and in vivo models.
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